- Home
- ECCC vs SNN Comparison
ECCC vs SNN Comparison
Compare ECCC & SNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ECCC | SNN |
|---|---|---|
| Founded | N/A | 1856 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Industrial Specialties |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | 12.3B |
| IPO Year | 2014 | 2002 |
Fundamental Metrics
Financial Performance| Metric | ECCC | SNN |
|---|---|---|
| Price | $24.90 | $27.46 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $36.25 |
| AVG Volume (30 Days) | 2.9K | ★ 1.7M |
| Earning Date | N/A | 03-16-2026 |
| Dividend Yield | N/A | ★ 2.48% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $8.58 |
| Revenue Next Year | N/A | $5.60 |
| P/E Ratio | ★ N/A | $64.97 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $23.02 | $27.56 |
| 52 Week High | $25.50 | $38.44 |
Technical Indicators
Market Signals| Indicator | ECCC | SNN |
|---|---|---|
| Relative Strength Index (RSI) | 46.68 | 31.53 |
| Support Level | $24.68 | N/A |
| Resistance Level | $24.91 | $31.36 |
| Average True Range (ATR) | 0.21 | 0.53 |
| MACD | -0.02 | -0.13 |
| Stochastic Oscillator | 7.94 | 0.92 |
Price Performance
Historical ComparisonAbout ECCC Eagle Point Credit Company Inc. 6.50% Series C Term Preferred Stock due 2031
Eagle Point Credit Co is an externally managed, non-diversified, closed-end management investment company. The Company's primary investment objective is to generate high current income, with a secondary objective to generate capital appreciation. The Company seeks to achieve its investment objectives by investing in equity and junior debt tranches of CLOs.
About SNN Smith & Nephew SNATS Inc.
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 40% of the UK-based firm's revenue comes from orthopedic products, and another 31% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the US, just over 30% is from other developed markets, and emerging markets account for the remainder.